Wire Stories
Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR�
U.S. Clinical Trial Commencement Anticipated in 1Q2023 BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing...